Clinical trials: Renal Allograft
- Condition Renal Allograft
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Transplant;Failure,Kidney
Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients
Detecting allograft injury and rejection is critical to preventing graft loss. The current standard of care (SoC) relies on serum creatinine (SC) and biopsy to monitor for and identify kidney injury earlier.
- Trial name
- QIDNEY (NCT03765203)
- Testing
- Natera KidneyScan, Clinical Performance and Value Vignettes
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Kidney Transplant Rejection
Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance
Prospective Observational Multicenter Cohort. External validation of donor derived cell free DNA in Renal Transplantation. Assessing performance of dd-cfDNA as a surveillance tool and its association with clinical outcomes.
- Trial name
- ADMIRAL (NCT04566055)
- Testing
- AlloSure
- Where
- 8 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CareDx
Kidney Transplant Rejection
Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry
This is an observational study to evaluate safety and efficacy outcomes in renal transplant recipients in whom post-transplant care is managed using AlloSure®.
- Trial name
- KOAR (NCT03326076)
- Testing
- Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney)
- Where
- 72 sites in United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- CareDx